A major dogma in cancer research is that cancer begins at the cellular level. Because of this single-cell origin, evolutionary principles have often been used to explain how somatic cancer cells are selected at a sub-individual level. The traditional application of Darwinian theory, however, in which the colony of cells constituting an individual is regarded as a whole, has not been applied extensively to the understanding of cancer until recently. Two proponents for this view, Breivik and Gaudernack, have suggested that in certain situations the cost of DNA repair might exceed the cost of errors. This model predicts that genetic stability is configured for an optimal cost-benefit relationship. Natural selection is not expected to have produced the best genetic stability available in the human body, merely the best compromise of DNA repair and costs. Repair and maintenance of the vast human genome is thermodynamically expensive, and an optimal balance between DNA repair and dietary needs is likely to have originated. Furthermore, fast growth conveys significant advantages such as early maturation or cognitive development, but usually at the expense of replication accuracy. Thus, a compromise between growth speed and cancer risk is likely to have taken place. These and other ecological mechanisms have probably prevented genomic stability to reach its full potential in the human body. In contrast, germ lines express near perfect DNA maintenance. Although germ cells are specialized DNA-conserving cells with few other functions, it's not given that their proteins will all be incompatible with the somatic cell. One approach to study this would be to systematically explore which DNA-stability and -repair systems are unique in germ cells, and induce their expression in invertebrate and mammalian model organisms. This could unveil which DNA-repair systems are switched off in the somatic cell lines, as they are incompatible, and which are absent due to evolution. The present review discuss different DNA-repair systems and cell cycle check point control mechanisms shown to be different or unique in the germ cell, and how they may be utilized in cancer therapy. Cancer Gene Therapy (2012) 19, 299-302; doi:10.1038/cgt.2012.1; published online 10 February 2012
Review
As an outsider to the field of cancer research, I have noticed the major dogma that cancer begins at the cellular level. A mutation occurs in a single somatic cell, which is passed along to its progeny, bypassing intracellular and immunological control systems. Because of the single-cell origin of the first cancer cell, evolutionary principles have often been used to explain how somatic cells are selected at a sub-individual level by carcinogenic mutations, providing them a shorter cell cycle than surrounding mitogen-controlled cells. The common denominator for these theories is that evolution is brought down on the cellular level, utilizing mechanisms usually applied to single cell organisms.
The more traditional application of Darwinist theory, in which the colony of cells constituting an individual is regarded as a whole, has not been applied extensively to the understanding of cancer until recently. Two proponents for this view, Breivik and Gaudernack, 1,2 have proposed that in some tissues during some conditions, the cost of DNA repair might exceed the cost of errors. This model predicts that genetic stability is configured for an optimal cost-benefit relationship. In other words, natural selection is not expected to have produced the best genetic stability available in the human body, merely the best compromise of DNA repair and the cost of these systems.
This premise, as pointed out by Breivik 3 and several others, is unique to the animal kingdom. In contrast to unicellular organisms, animals have separated cell lines to conserve genome information and express the phenotype. These distinct cell types, the germinal and somatic cell lines, have greatly different demands for genetic stability. The germinal line carries the genetic information to the offspring and must have near-perfect replication of the genome. The somatic cell line is only important for the phenotype, and is otherwise an evolutionary deadend. For the cells composing our bodies, we can predict several compromises between genetic stability and other needs, such as: Natural selection therefore has not favored the most stable genomes but rather those that represented the best compromises between growth, calorie demand, longevity and cancer rate (and likely many other factors). In contrast, germ-line DNA replication and maintenance is near perfect. The superiority of germ cell DNA stability is especially evident in the male; premeiotic male germ cells divide more than 1000 times before entering meiosis in a 50-year-old male. 4 Despite this, late paternity is only slightly associated with genetic defects measured as for example stillbirths. 5 This astounding accuracy of replication and conservation must include repair systems that are not as efficient, not as expressed or simply not present in the somatic cell. Thus, differences in the expressional patterns of these two cell lines could reveal what DNArepair systems explain this enormous gap in genomic stability and accuracy of replication. Despite the obvious informational value of this dichotomy, there have to date been very few studies comparing DNA-repair systems in somatic and germinal cells. Still, aided by a recent and very comprehensive review by Ozturk et al., 6 I have been able to find a few comparisons revealing differences in the DNA maintenance and cell cycle control of germ cells and somatic cells.
One striking difference is that the homologous recombination system for double strand breakup repair is more commonly used in the germ cell (data are from oocytes and blastocytes) compared with non-homologous strand joining, which is far more error prone and used in the somatic cell. 7, 8 A system that appears to have an unique role in germ cells to facilitate cell cycle control are ataxia telangiectasia (Atm) and Atm, and Rad3-related (Atr) cell cycle control system, which detects DNA damage and may facilitate cell cycle arrest. 9 Other interesting regulation of repair genes has been seen in mouse spermatogenic cells, where ligase 1, ligase III, Ape, Xrcc1 and PolB had higher levels compared to somatic cells. 10 One of the most promising proteins shown to contribute significantly to germ cell DNA stability, however, are poly ADP-ribose polymerase 1.
11 Recent studies 12 indicate that it is most important in excision repair and remodelling of chromatin structure after DNA damage. It can assist the 20S proteasome to degrade damaged histone proteins and facilitate access to other repair proteins. 13 Furthermore, poly ADP-ribose polymerase 1 interacts with several proteins, including telomerase, p21, check point proteins, ligases, NF-kB and p53.
The proteins mentioned above are likely to represent only a fraction of the DNA-repair systems that differ between germ-and somatic cells. They may explain part of the difference in genetic stability, however, and some may satisfy an important condition necessary for clinical application; that the germ cell DNA-repair protein may function in the somatic cell without serious side effects.
In addition to DNA repair, another known difference between germ cells and somatic cells are cell cycle checkpoint control. In somatic cells, cell cycle arrest at G1/S occur before DNA synthesis and arrest at G2/M occur before mitosis. 14, 15 In germ cells from human embryos, however, there seems to be no checkpoint. Instead, apoptosis is triggered to completely remove the blastomere or blastocyte. 16, 17 This preference for an apoptotic outcome is consistent with a high expression of pro-apoptotic Bax and Bak genes and low expression of anti-apoptotic genes such as Bcl-2 and Bcl-w in MII oocytes and blastocytes. 7 This preference of the germ cell for apoptosis rather than repair is very interesting in light of synthetic lethality, a novel approach within cancer therapy that utilizes mutations to make only the cancer cell and not surrounding tissue susceptible to a tailored drug. The drug will only induce apoptosis in cells sensitized to the drug by the cancer-causing mutation, and will not affect healthy cells. 18 The aggressive apoptosis pathway of germ cells could have a similar therapeutic use if expressed in somatic tissues. The cancer cell, which surpassed somatic checkpoint control, has never been exposed to the corresponding apoptosis control of germ cells, and will likely be sensitive to such an intervention. However, clinical use would depend greatly on specificity; too easily triggered apoptosis would obviously be very damaging to healthy tissues. On the other hand, if germ-cell apoptosis systems expressed in somatic cells were not efficient enough, synthetic lethality and germ-cell apoptosis control could constitute a potent combination therapy. This strategy is especially relevant as the major endpoint of synthetic lethality treatment is apoptosis of the targeted cancer cell line. 18 Many germ-line DNA-repair systems would not work in all tissues, however, as they likely require cellular compartments or facilities of the cell that are not available. Some cells, such as neurons, have an absent or greatly reduced rate of cell division, and would enjoy limited benefits from more accurate DNA replication. If too extensive and energy-intensive DNA-repair systems were to be activated, they might challenge temperature homeostasis or oxygen tension of sensitive organs, such as the human brain. Finally, in tissues where regrowth rates are critical, such as the colon epithelium, any repair mechanism that delays cell division might be disadvantageous for the function of that organ. It therefore goes without question that many or most germ-cell quality DNA-repair systems would be incompatible with the somatic cell or cause serious side effects. Successfully establishing only a fraction of the genomic stability of germ cells in select organs, however, could considerably reduce risk in cancer-exposed patient groups (Figure 1 ). Perhaps even more important, if the strict apoptosis control of germ cells could be used to target cancer in somatic cells, a real alternative to chemotherapy and radiation could be a possibility.
In my opinion, gene therapy will provide the most suitable tools (siRNA/antisense therapeutics) to explore the potential of germ cell proteins in somatic tissues. The alternative path would be to identify DNA-binding proteins that regulate DNA repair in germ cells, and adapt these for pharmacological use. Regulatory proteins of this type often have multiple effects, which change according to the situation, and are therefore poorly suited to give answers about how a specific germinal protein behaves in various tissues. For these reasons gene therapy will undoubtedly provide the most controlled and targeted approach to study germ cell DNA repair and apoptosis control in the somatic cell.
The perhaps most straightforward way to exploit the possibilities outlined in the present review would be to systematically explore which DNA-repair systems are exclusively expressed in ageless germ cells, and thereafter induce their expression in invertebrate and mammalian model organisms such as C. elegans and the mouse. This could provide insight into what DNA-repair systems are switched off in the somatic cell lines because they do not function there, and what repair mechanisms are absent simply because our evolution did not permit their presence. Repair systems that are shut down in somatic cells due to an evolutionary-based demand for a more energy-efficient metabolism or faster growth could prove invaluable tools in cancer treatment.
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Genetic stability Figure 1 Schematic view of how genetic stability favors less cancer risk and longevity at the expense of other factors, such as growth rate, tissue regeneration and calorie demand.
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